Nastaran Khodadad

Dr. Nastaran Khodadad

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 August 2024 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
AHAva Hashempour
Ava Hashempour
NKNastaran Khodadad
Nastaran Khodadad
SAShokufeh Akbarinia
Shokufeh Akbarinia
FGFarzane Ghasabi
Farzane Ghasabi
YGYounes Ghasemi
Younes Ghasemi
SFShahab Falahi
Shahab Falahi
Substantial advances have been made in the development of promising HIV vaccines to eliminate HIV-1 infection. For the first time, one hundred of the most submitted HIV subtypes and CRFs were retrieved from the LANL database, and the consensus sequences of the eleven HIV proteins were obtained to design vaccines for human and mouse hosts. By using various servers and filters, highly qualified B-cell epitopes, as well as HTL and CD8 + epitopes that were common between mouse and human alleles and were also located in the conserved domains of HIV proteins, were considered in the vaccine constructs. With 90% coverage worldwide, the human vaccine model covers a diverse allelic population, making it widely available. Codon optimization and in silico cloning in prokaryotic and eukaryotic vectors guarantee high expression of the vaccine models in human and E. coli hosts. Molecular dynamics confirmed the stable interaction of the vaccine constructs with TLR3, TLR4, and TLR9, leading to a substantial immunogenic response to the designed vaccine. Vaccine models effectively target the humoral and cellular immune systems in humans and mice; however, experimental validation is needed to confirm these findings in silico.

23 September 2021 in Future Virology
Verified
Journal Article
Closed access
NKNastaran Khodadad
Nastaran Khodadad
SSSeyed Saeed Seyedian
Seyed Saeed Seyedian
SHSomayeh Biparva Haghighi
Somayeh Biparva Haghighi
MMManoochehr Makvandi
Manoochehr Makvandi
Aim: Chronic hepatitis B infection is the main cause of liver complications such as hepatic failure, liver cirrhosis and hepatocellular carcinoma (HCC). In this study, we attempted to evaluate mole...

20 September 2024 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
AHAva Hashempour
Ava Hashempour
NKNastaran Khodadad
Nastaran Khodadad
SAShokufeh Akbarinia
Shokufeh Akbarinia
FGFarzane Ghasabi
Farzane Ghasabi
YGYounes Ghasemi
Younes Ghasemi
SFShahab Falahi
Shahab Falahi

17 February 2025 in Biochemistry and Biophysics Reports
Verified
Journal Article
Open access
AHAva Hashempour
Ava Hashempour
SAShokufeh Akbarinia
Shokufeh Akbarinia
NKNastaran Khodadad
Nastaran Khodadad
FSFarimah Safari
Farimah Safari
ZMZeinab Mehrabi
Zeinab Mehrabi
HIV-1 has various subtypes and CRFs, each with unique genetic attributes that impact the virus's spread, disease development, and response to treatment in different populations. Determining V3 tropism is crucial for utilizing CCR5 antagonists and understanding why certain HIV-1 subtypes are more pathogenic than others are. Genotypic coreceptor usage of 603 major subtypes of A, B, C, AE, and CRF35-AD is investigated via five bioinformatics tools (PhenoSeq, WebPSSM, Geno2Pheno, Net charge, and the 11/25 rule). This study examined crown motifs, N-glycosylation sites, and T8V mutations in all subtypes. R5 viruses are common in subtypes A, B, C, and CRF35-AD. These data indicate that R5 viruses in subtypes A and B are more prone to crown motif formation. The first report assessed the tropism of common HIV-1 subtypes and reported that CCR5 inhibitors could help treat patients with all subtypes but not AE. WebPSSM is a suitable method for determining HIV-1 tropism in different subtypes. Finally, large cohorts to assess virological response to CCR5 inhibitors would provide deep insight into the practicality of genotypic methods in clinical settings.

1 August 2024 in AIDS Research and Human Retroviruses
Verified
Journal Article
Closed access
FGFarzaneh Ghassabi
Farzaneh Ghassabi
NKNastaran Khodadad
Nastaran Khodadad
BDBehzad Dehghani
Behzad Dehghani
ZHZahra Hasanshahi
Zahra Hasanshahi
NKNastaran Khodadad
Nastaran Khodadad
MDMohamad Ali Davarpanah
Mohamad Ali Davarpanah
Background Glycoprotein 41 (gp41) of the human immunodeficiency virus type 1 (HIV-1) protein plays a critical role in membrane fusion. Gp41 binds to proteins in the plasma membrane of CD4+ T cells, particularly the T-cell antigen receptor (TCR). These findings indicate that gp41 is involved in the assembly of HIV-1 at the plasma membrane of T cells and affects the stimulation of the TCR. To control HIV-1, new inhibitors were introduced to target the gp41 protein. However, mutations in this region might reduce their efficacy. Materials and Methods The Gp41 region was amplified from the sera of thirty patients using nested polymerase chain reaction (PCR). The sequences were analyzed by bioinformatics tools to identify mutations and gp41 structural features. Subtyping and the interaction between fusion inhibitors and gp41 proteins were also examined. Results As the first report from Iran, docking analysis between fusion inhibitors and Iranian gp41 proteins showed that mutations in gp41 could not reduce the efficacy of the fusion inhibitors. Most of the patients were infected with CRF35-AD. Several postmodification positions, including glycosylation and phosphorylation sites, were identified in the gp41 protein. Conclusion Our findings revealed no known multinational drug resistance to gp41 inhibitors; thus, fusion inhibitors can effectively inhibit HIV in Iranian patients. Additionally, the present study introduced a new gp41 region (36-44 aa), which considerably influences the interactions between gp41 inhibitors and the gp41 protein. This region may play a pivotal role in suppressing gp41 inhibitors in CFR35-AD. Furthermore, gp41 can be considered a good target for subtyping analysis via the phylogenetic method.

4 March 2026 in Future Virology
Verified
Journal Article
Closed access
NKNastaran Khodadad
Nastaran Khodadad
MZMilad Zandi
Milad Zandi
SAShokufeh Akbarinia
Shokufeh Akbarinia
MFMona Fani
Mona Fani
SSShokrollah Salmanzadeh
Shokrollah Salmanzadeh
SASamaneh Abbasi
Samaneh Abbasi